research use only

NMDA (N-Methyl-D-aspartic acid) NMDAR agonist

Name: NMDA (N-Methyl-D-aspartic acid)
Brand: Selleck Chemicals
SKU: S7072
Availability: InStock
Rating: 5 (11 reviews)

Cat.No.S7072

NMDA (N-Methyl-D-aspartic acid) is a specific agonist for the NMDA receptor, mimicking the action of glutamate, the neurotransmitter which normally acts at that receptor. Phase 4.

Chemical Structure

Molecular Weight: 147.13

Jump to

Quality Control

Batch: Purity: 100.00%

100.00

Related Targets	Adrenergic Receptor AChR 5-HT Receptor COX Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE)
Other NMDAR Inhibitors	(+)-Dizocilpine (MK 801) Maleate (-)-Dizocilpine (MK 801) Maleate Ifenprodil Tartrate Memantine HCl Spermidine trihydrochloride Kynurenic acid Mephenesin Quinolinic acid Radiprodil (RGH-896) NMDAR antagonist 1

Solubility

In vitro
Batch:

Water : 29 mg/mL

DMSO : 15 mg/mL (101.95 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.750mg/ml (5.10mM)
	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.750mg/ml (5.10mM)
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	147.13	Formula	C₅H₉NO₄	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	6384-92-5	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	CNC(CC(=O)O)C(=O)O

Mechanism of Action

Targets/IC₅₀/Ki	NMDA receptor
In vitro	NMDA (N-Methyl-D-aspartic acid) is an excitatory amino acid neurotransmitter that specifically binds to the NR2 subunits of its receptor without affecting other glutamate receptors (such as those for AMPA and kainate). This compound stimulates the opening of a non-specific cation channel, allowing the passage of Ca²⁺ and Na²⁺ into the cell and K⁺ out of the cell. Its activation can produce excitatory postsynaptic potentials (EPSP) and trigger an increase in intracellular Ca²⁺ content, which may further participate in various signaling pathways. The NMDA receptor plays a key role in a wide range of physiological (e.g., long-term potentiation and neuronal plasticity) and pathological processes (e.g., excitotoxicity and epilepsy).
References	[1] https://pubmed.ncbi.nlm.nih.gov/11399431/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06236451	Recruiting	Schizophrenia	All India Institute of Medical Sciences Bhubaneswar	April 5 2024	Phase 4
NCT06185790	Recruiting	Mitochondrial Diseases\|Diabetes-Deafness Syndrome Maternally Transmitted	Radboud University Medical Center\|Stichting Stofwisselkracht	January 5 2024	Not Applicable
NCT05954468	Recruiting	NMDAR Antibody-associated Auto-immune Encephalitis	Hospices Civils de Lyon	October 9 2023	--
NCT06183788	Recruiting	Anti-NMDA Receptor Encephalitis	Fundacion Clinic per a la Recerca Biomédica\|Hospital Sant Joan de Deu	January 16 2023	Not Applicable
NCT05650229	Active not recruiting	Primary Mitochondrial Disease	Abliva AB	December 13 2022	Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):